FDA clearance is a critical regulatory milestone for biotech companies, especially those involved in developing genetic therapies. This approval not only validates the company's research and development efforts but also significantly enhances its credibility and potential for future success. The initiation of Phase 1/2 clinical trials is a positive development that could lead to increased investor confidence and potentially positive stock price movement in the short term.